- ISIN
- US00287Y1091
- CUSIP
- 00287Y109
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- IPO Date
- Jan 2, 2013
Highlights
- Market Cap
- $408.04B
- Enterprise Value
- $479.83B
- EPS (TTM)
- $2.05
- PE Ratio
- 112.07
- Total Revenue (TTM)
- $62.82B
- Gross Profit (TTM)
- $46.15B
- EBITDA (TTM)
- $17.96B
- Year Range
- $181.73 - $244.81
- Target Price
- $256.69
- ROA (TTM)
- 2.67%
- ROE (TTM)
- 13.23%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ABBV Performance Chart
AbbVie Inc. (ABBV) is up 2.3% since the beginning of the year. At $230 per share, ABBV is trading 6.0% below its 52-week high of $245. Investors who bought $1,000 worth of ABBV shares 5 years ago would now be looking at an investment worth $2,434.
Loading charts...
Returns By Period
AbbVie Inc. (ABBV) has returned 2.32% so far this year and 28.17% over the past 12 months. Looking at the last ten years, ABBV has achieved an annualized return of 19.22%, outperforming the S&P 500 Index benchmark, which averaged 13.88% per year.
AbbVie Inc.
- 1D
- 6.25%
- 1M
- 6.63%
- YTD
- 2.32%
- 6M
- 2.58%
- 1Y
- 28.17%
- 3Y*
- 23.52%
- 5Y*
- 19.47%
- 10Y*
- 19.22%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
ABBV Monthly Returns History
Based on dividend-adjusted daily data since Jan 2, 2013, ABBV's average daily return is +0.09%, while the average monthly return is +1.75%. At this rate, an investment would double in approximately 3.3 years.
Historically, 62% of months were positive and 38% were negative. The best month was Nov 2020 with a return of +22.9%, while the worst month was Mar 2018 at -18.3%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 5 months.
On a daily basis, ABBV closed higher 54% of trading days. The best single day was Jan 26, 2018 with a return of +13.8%, while the worst single day was Jun 25, 2019 at -16.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -1.61% | 4.07% | -6.29% | -2.03% | 3.03% | 5.64% | 2.32% | ||||||
| 2025 | 4.46% | 13.67% | 0.23% | -6.02% | -4.61% | -0.26% | 2.71% | 11.31% | 10.05% | -5.15% | 4.43% | 0.35% | 33.08% |
| 2024 | 7.10% | 7.09% | 3.44% | -9.85% | -0.86% | 6.38% | 9.04% | 5.93% | 0.60% | 4.06% | -10.27% | -2.86% | 18.86% |
| 2023 | -7.71% | 4.16% | 3.55% | -4.30% | -8.71% | -2.34% | 12.25% | -1.75% | 1.43% | -4.34% | 0.86% | 8.83% | -0.23% |
| 2022 | 2.15% | 7.95% | 9.70% | -8.62% | 0.33% | 3.93% | -5.42% | -6.31% | -0.19% | 10.19% | 10.10% | 0.27% | 24.01% |
| 2021 | -3.24% | 5.13% | 0.45% | 4.28% | 1.52% | -0.49% | 4.40% | 3.85% | -10.69% | 7.59% | 0.53% | 17.45% | 32.43% |
Benchmark Metrics
AbbVie Inc. has an annualized alpha of 12.98%, beta of 0.68, and R2 of 0.19 versus S&P 500 Index. Calculated based on daily prices since January 02, 2013.
- This stock captured 116.21% of S&P 500 Index gains but only 86.64% of its losses - a favorable profile for investors.
- Beta of 0.68 may look defensive, but with R2 of 0.19 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.19 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 12.98%
- Beta
- 0.68
- R²
- 0.19
- Upside Capture
- 116.21%
- Downside Capture
- 86.64%
Return for Risk
Risk / Return Rank
ABBV ranks 71 for risk / return — better than 71% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for AbbVie Inc. (ABBV) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ABBV | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.90 | ||
| Sortino ratioReturn per unit of downside risk | -1.04 | ||
| Omega ratioGain probability vs. loss probability | 1.21 | 1.37 | -0.16 |
| Calmar ratioReturn relative to maximum drawdown | 1.63 | 2.78 | -1.15 |
| Martin ratioReturn relative to average drawdown | 3.63 | 12.44 | -8.81 |
Dividends
Dividend History
AbbVie Inc. provided a 2.93% dividend yield over the last twelve months, with an annual payout of $6.74 per share. The company has been increasing its dividends for 12 consecutive years.
| Period | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | $6.74 | $6.56 | $6.20 | $5.92 | $5.64 | $5.20 | $4.72 | $4.28 | $3.59 | $2.56 | $2.28 | $2.02 |
Dividend yield | 2.93% | 2.87% | 3.49% | 3.82% | 3.49% | 3.84% | 4.41% | 4.83% | 3.89% | 2.65% | 3.64% | 3.41% |
Monthly Dividends
The table displays the monthly dividend distributions for AbbVie Inc.. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | $1.73 | $0.00 | $0.00 | $1.73 | $0.00 | $0.00 | $3.46 | ||||||
| 2025 | $1.64 | $0.00 | $0.00 | $1.64 | $0.00 | $0.00 | $1.64 | $0.00 | $0.00 | $1.64 | $0.00 | $0.00 | $6.56 |
| 2024 | $1.55 | $0.00 | $0.00 | $1.55 | $0.00 | $0.00 | $1.55 | $0.00 | $0.00 | $1.55 | $0.00 | $0.00 | $6.20 |
| 2023 | $1.48 | $0.00 | $0.00 | $1.48 | $0.00 | $0.00 | $1.48 | $0.00 | $0.00 | $1.48 | $0.00 | $0.00 | $5.92 |
| 2022 | $1.41 | $0.00 | $0.00 | $1.41 | $0.00 | $0.00 | $1.41 | $0.00 | $0.00 | $1.41 | $0.00 | $0.00 | $5.64 |
| 2021 | $1.30 | $0.00 | $0.00 | $1.30 | $0.00 | $0.00 | $1.30 | $0.00 | $0.00 | $1.30 | $0.00 | $0.00 | $5.20 |
Dividend Yield & Payout
Dividend Yield
AbbVie Inc. has a dividend yield of 2.93%, which is quite average when compared to the overall market.
Payout Ratio
AbbVie Inc. has a payout ratio of 239.96%, which is above the market average. This might signify the company's strong earnings or financial health. However, it could also hint at a more mature business phase with potentially slower growth.
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the AbbVie Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the AbbVie Inc. was 45.09%, occurring on Aug 15, 2019. Recovery took 330 trading sessions.
The current AbbVie Inc. drawdown is 3.65%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2019 bear market2019 | -45.09%Aug 2019 | 1y 6mo | 1y 3mo | 2y 10moJan 2018 - Dec 2020 |
2015 bear market2015 | -31.61%Oct 2015 | 2mo 25d | 1y 6mo | 1y 9moJul 2015 - May 2017 |
Bear market2022 | -21.92%Sep 2022 | 5mo 22d | 1y 3mo | 1y 9moApr 2022 - Jan 2024 |
2025 selloff2025 | -20.74%Apr 2025 | 1mo 11d | 4mo 16d | 5mo 27dMar 2025 - Sep 2025 |
2015 correction2015 | -19.82%Feb 2015 | 2mo 3d | 4mo 9d | 6mo 12dDec 2014 - Jun 2015 |
Drawdown Indicators
| ABBV | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -45.09% | -56.78% | +11.69% |
Max Drawdown (1Y)Largest decline over 1 year | -17.32% | -9.10% | -8.22% |
Max Drawdown (3Y)Largest decline over 3 years | -20.74% | -18.90% | -1.84% |
Max Drawdown (5Y)Largest decline over 5 years | -21.92% | -25.43% | +3.51% |
Max Drawdown (10Y)Largest decline over 10 years | -45.09% | -33.92% | -11.17% |
Current DrawdownCurrent decline from peak | -3.65% | -1.80% | -1.85% |
Average DrawdownAverage peak-to-trough decline | -10.71% | -10.71% | 0.00% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 7.78% | 2.03% | +5.75% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of AbbVie Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how AbbVie Inc. is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for ABBV, comparing it with other companies in the Drug Manufacturers - General industry. Currently, ABBV has a P/E ratio of 112.1. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ABBV relative to other companies in the Drug Manufacturers - General industry. Currently, ABBV has a P/S ratio of 6.5. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ABBV in comparison with other companies in the Drug Manufacturers - General industry. Currently, ABBV has a P/B value of 14.8. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ABBV
Add AbbVie Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ABBV